Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Author

  • Jessica L Mega
  • Nathan O Stitziel
  • Gustav Smith
  • Daniel I Chasman
  • Mark J Caulfield
  • James J Devlin
  • Francesco Nordio
  • Craig L Hyde
  • Christopher P Cannon
  • Frank M Sacks
  • Neil R Poulter
  • Peter S Sever
  • Paul M Ridker
  • Eugene Braunwald
  • Olle Melander
  • Sekar Kathiresan
  • Marc S Sabatine

Summary, in English

Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.

Department/s

  • Cardiology
  • Cardiovascular Research - Hypertension
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2015

Language

English

Pages

2264-2271

Publication/Series

The Lancet

Volume

385

Issue

9984

Document type

Journal article

Publisher

Elsevier

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

Research group

  • Cardiovascular Research - Hypertension

ISBN/ISSN/Other

  • ISSN: 1474-547X